Candel Therapeutics, Inc. has disclosed a stock option transaction involving its director, Paul B. Manning. This transaction is significant as it highlights the company's compensation practices and the alignment of executive interests with those of shareholders.
Background
Candel Therapeutics, Inc. is a company focused on the development of biological products, specifically in the area of therapeutic solutions. The company is classified under the SIC code 2836, which pertains to Biological Products, (No Diagnostic Substances). Candel trades on the Nasdaq under the ticker symbol CADL. Recent filings indicate that the company is categorized as an emerging growth company.
What the Filing Says
According to the recent filing dated October 2, 2026, Manning exercised stock options to acquire 2,189 shares at a price of $10.44 per share. The transaction occurred on September 30, 2026, at a price of $8.676 per share, and Manning now owns 2,189 shares following this transaction. The filing notes that this award was granted in lieu of normal quarterly cash payments and that the underlying award quantity is fully vested at the time of grant.
Impact
This transaction may affect various stakeholders, including shareholders who are keen on understanding how executive compensation aligns with company performance. Additionally, it may influence the perceptions of analysts and investors regarding Candel's governance practices and future growth potential.
What's Next
The filing does not say what happens next.